{"id":734,"date":"2026-10-19T21:12:37","date_gmt":"2026-10-20T01:12:37","guid":{"rendered":"http:\/\/novameds.local\/ca\/?post_type=product&#038;p=734"},"modified":"2026-10-19T21:58:06","modified_gmt":"2026-10-20T01:58:06","slug":"catalog-ll-37-cap-18-5-mg","status":"publish","type":"product","link":"https:\/\/novameds.health\/ca\/product\/catalog-ll-37-cap-18-5-mg\/","title":{"rendered":"LL-37 (CAP-18) 5mg"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Composition and product details\">\n<h2>Composition and product details<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>Overview<\/h2>\n<div>\n<p>LL-37 (CAP-18) is the active C-terminal peptide derived from human cathelicidin, the sole cathelicidin-family antimicrobial peptide encoded in the human genome. Research interest centers on its dual function as both a direct membrane-disrupting antimicrobial agent and an immunomodulatory signalling molecule engaging multiple receptor pathways.<\/p>\n<p>Research applications include innate immune signalling studies, antimicrobial peptide membrane-interaction research, and formyl peptide receptor (FPR2) pathway investigation.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/16198951\" target=\"_blank\" rel=\"noopener noreferrer\">Molecular data on PubChem<\/a><\/p>\n<div>\n<div><span>LL-37 (CAP-18) 5mg<\/span><span>1 vial | KIT (10 vials)<\/span><\/div>\n<\/div><\/div>\n<\/p><\/div>\n<div>\n<h2>Properties<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C205H340N60O53<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>Cathelicidin, ropocamptide, Bac4, Cathelicidin antimicrobial peptide 18<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>4493 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>154947<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>16198951<\/td>\n<\/tr>\n<tr>\n<th>Available formats<\/th>\n<td>1 vial \u00b7 KIT (10 vials)<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>36 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Research<\/h2>\n<p>\t\t\t\t\t<span>LL-37 is a 37-residue amphipathic alpha-helical peptide cleaved from the precursor protein hCAP-18, and is studied for two distinct but related activities: direct antimicrobial action via membrane permeabilisation of bacterial cell envelopes, and immunomodulatory signalling through host receptors including formyl peptide receptor 2 (FPR2), P2X7 purinergic receptor, and epidermal growth factor receptor (EGFR) transactivation pathways. In vitro models examine LL-37&#8217;s chemotactic effects on immune cells (neutrophils, monocytes, mast cells), its capacity to neutralise bacterial endotoxin (LPS), and its role in wound-healing-associated cell migration and angiogenesis signalling. Membrane-interaction biophysics (using model lipid bilayers) and cell-based immune signalling assays are standard experimental approaches for this peptide. Independently third-party HPLC-tested; COA available per batch.<br \/>\n<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What is the proposed dual mechanism of LL-37&#8217;s antimicrobial and immunomodulatory activity?<\/span><\/p>\n<\/summary>\n<div>\n<p>LL-37&#8217;s antimicrobial mechanism involves direct insertion into and disruption of bacterial cell membranes via its amphipathic alpha-helical structure, a mechanism studied using model lipid bilayer and liposome leakage assays.<\/p>\n<p>Separately, LL-37 engages host cell surface receptors \u2014 including FPR2, P2X7, and EGFR transactivation pathways \u2014 to modulate immune cell chemotaxis, cytokine release, and cell migration, representing a receptor-mediated signalling mechanism distinct from its direct membrane-disrupting antimicrobial action.<\/p>\n<p>Research distinguishing these two activities typically uses peptide fragments or receptor antagonists to isolate which mechanism drives a given experimental endpoint.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What cell-based assays are used to study LL-37&#8217;s chemotactic and immunomodulatory effects?<\/span><\/p>\n<\/summary>\n<div>\n<p>Standard approaches include transwell migration assays to quantify LL-37-induced chemotaxis of neutrophils, monocytes, or mast cells, alongside cytokine\/chemokine release assays (ELISA, multiplex) following LL-37 exposure in immune cell culture models. FPR2-specific signalling is often confirmed using selective FPR2 antagonists or receptor-knockdown approaches to establish receptor dependence of the observed chemotactic or signalling response.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How is LL-37&#8217;s membrane-disrupting antimicrobial mechanism studied using biophysical methods?<\/span><\/p>\n<\/summary>\n<div>\n<p>Model lipid bilayer systems \u2014 including liposome dye-leakage assays, planar lipid bilayer electrophysiology, and circular dichroism spectroscopy to monitor peptide secondary structure upon membrane association \u2014 are standard biophysical methods for characterising LL-37&#8217;s membrane interaction and permeabilisation kinetics. These methods allow researchers to correlate peptide concentration, lipid composition (mimicking bacterial versus mammalian membranes), and resulting membrane disruption, providing mechanistic insight into the peptide&#8217;s selectivity for bacterial over host cell membranes.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>LL-37 (CAP-18) is the active C-terminal peptide derived from human cathelicidin, the sole cathelicidin-family antimicrobial peptide encoded in the human genome.<\/p>\n<p>Presentation: LL-37 (CAP-18) 5mg.<\/p>\n<p>Select the required strength and pack size.<\/p>\n<p class=\"nm-research-disclaimer\">For laboratory research only. Not for human or veterinary use.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Illustrative packaging generated with AI.<\/small><\/p>\n","protected":false},"featured_media":926,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[26],"product_tag":[],"nm_classification":[],"class_list":["post-734","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-regeneration","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product\/734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/comments?post=734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media\/926"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media?parent=734"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_brand?post=734"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_cat?post=734"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_tag?post=734"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/nm_classification?post=734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}